TP53 and RB1 knockout models exhibit enzalutamide resistance and the upregulation of basal markers, neuroendocrine markers, and lineage-defining and stemness-related transcription factors, as well as the downregulation of luminal cell markers; these changes often suggest a more aggressive tumor and worse prognostic outcome (Levine, 2020). This evidence concerns the gene TP53 and neoplasm.